Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

BACKGROUND: Not all patients with rheumatoid arthritis can tolerate or respond to methotrexate, a standard treatment for this disease. There is evidence that antitumour necrosis factor alpha (TNFalpha) is efficacious in relief of signs and symptoms. We therefore investigated whether infliximab, a ch...

Full description

Bibliographic Details
Main Authors: Maini, R, St Clair, E, Breedveld, F, Furst, D, Kalden, J, Weisman, M, Smolen, J, Emery, P, Harriman, G, Feldmann, M, Lipsky, P
Format: Journal article
Language:English
Published: 1999